Quick Answer
Corbus Pharmaceuticals Holdings, Inc. reported Operating Income of -$85.31 million for fiscal year 2025.
Corbus Pharmaceuticals Holdings, Inc. Operating Income — Annual History
| Fiscal Year | Operating Income | YoY Change |
|---|---|---|
| 2025 | -$85.31M | -75.1% |
| 2024 | -$48.72M | -8.1% |
| 2023 | -$45.08M | -13.2% |
| 2022 | -$39.84M | +28.9% |
| 2021 | -$55.99M | +54.4% |
| 2020 | -$122.81M | -59.3% |
| 2019 | -$77.10M | -35.9% |
| 2018 | -$56.75M | -74.3% |
| 2017 | -$32.56M | -62.9% |
| 2016 | -$19.99M | -125.7% |
| 2015 | -$8.85M | -234.5% |
| 2014 | -$2.65M | -375.0% |
| 2013 | -$557.3K | — |
Quarterly Operating Income
| Quarter Ending | Operating Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$24.42M | -57.5% | -27.5% |
| June 30, 2025 | -$19.15M | -74.3% | +3.2% |
| March 31, 2025 | -$19.77M | -105.5% | -27.5% |
| September 30, 2024 | -$15.51M | -63.4% | -41.1% |
| June 30, 2024 | -$10.99M | -34.2% | -14.2% |
| March 31, 2024 | -$9.62M | +44.4% | -1.4% |
| September 30, 2023 | -$9.49M | -16.0% | -15.9% |
| June 30, 2023 | -$8.19M | +33.6% | +52.7% |
- Corbus Pharmaceuticals Holdings, Inc. showed a decrease of -75.1% in Operating Income compared to the prior fiscal year.
- Over the 2013–2025 period, Corbus Pharmaceuticals Holdings, Inc.’s operating income has declined by 15208.4% (from -$557.3 thousand to -$85.31 million).
- The most recent figure is from Corbus Pharmaceuticals Holdings, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 9, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: